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Capecitabine, commonly used in different settings for
metastatic breast cancer, is an inactive prodrug that take
advantage of the tumor elevated levels of thymidine
phosphorylase (TP), a key enzyme for its conversion to
5-florouracil. Potentiation of anticancer activity of cape-
citabine is required to improve its therapeutic index.
We demonstrated that histone deacetylase inhibitors
(HDACi), including the anti-epileptic valproic acid (VPA),
induced dose and time-dependent upregulation of TP
transcript and protein in breast cancer cells but not in
non-tumorigenic MCF-10A cell line. By using siRNA or
isoform specific HDACi we demonstrated that HDAC-3 is
the main isoform whose inhibition is involved in TP mod-
ulation. Combined treatment of HDACi, including VPA,
and capecitabine resulted in synergistic/additive antiproli-
ferative and proapoptotic effects in all cell lines tested. TP
knockdown experiments demonstrated the crucial role of
TP modulation in the synergism observed. The synergistic
antitumor effect between VPA and capecitabine was also
demonstrated in vivo in a breast cancer xenograft model,
but not in xenografts from TP-knocked cells, confirming
in vitro data. Overall, this study suggests that the combina-
tion of an HDACi, such as valproic acid, and capecitabine,
is an innovative antitumour strategy and warrants further
clinical evaluation for the treatment of metastatic breast
cancer.
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